A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study

Vaccine

Volumn 29, Issue 16, 2011, Pages 2918-2932

  Ferrantelli, Flavia ^a   Maggiorella, Maria Teresa ^a   Schiavoni, Ilaria ^a   Sernicola, Leonardo ^a   Olivieri, Erika ^a   Farcomeni, Stefania ^a   Pavone Cossut, Maria Rosaria ^a   Moretti, Sonia ^a   Belli, Roberto ^a   Collacchi, Barbara ^a   Srivastava, Indresh K ^b   Titti, Fausto ^a   Cafaro, Aurelio ^a   Barnett, Susan W ^b   Ensoli, Barbara ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

HIV AIDS vaccine; Mucosal R5 SHIV challenge; Neutralizing antibodies

Indexed keywords

TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; EPITOPE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IMMUNOGENICITY; MACACA; MALE; NONHUMAN; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPE MAPPING; HIV ANTIBODIES; HIV INFECTIONS; IMMUNITY, CELLULAR; MACACA FASCICULARIS; MALE; PILOT PROJECTS; RNA, VIRAL; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 79953211067     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.006     Document Type: Article

References (76)

1. Ferrantelli F., Cafaro A., Ensoli B. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Curr Opin Biotechnol 2004, 15:543-556.
2. Girard M.P., Bansal G.P. HIV/AIDS vaccines: a need for new concepts?. Int Rev Immunol 2008, 27:447-471.
3. Bansal G.P., Malaspina A., Flores J. Future paths for HIV vaccine research: exploiting results from recent clinical trials and current scientific advances. Curr Opin Mol Ther 2010, 12:39-46.
4. Letvin N.L., Barouch D.H., Montefiori D.C. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 2002, 20:73-99.
5. Demberg T., Florese R.H., Heath M.J., Larsen K., Kalisz I., Kalyanaraman V.S., et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2007, 81:3414-3427.
6. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993, 67:277-287.
7. Chang H.K., Gallo R.C., Ensoli B. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein. J Biomed Sci 1995, 2:189-202.
8. Ensoli B., Cafaro A., Caputo A., Fiorelli V., Ensoli F., Gavioli R., et al. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env. Microbes Infect 2005, 7:1392-1399.
9. Ensoli B. Rational vaccine strategies against AIDS: background and rationale. Microbes Infect 2005, 7:1445-1452.
10. Ensoli B. Criteria for selection of HIV vaccine candidates-general principles. Microbes Infect 2005, 7:1433-1435.
11. Ensoli B., Fiorelli V., Ensoli F., Cafaro A., Titti F., Buttò S., et al. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS 2006, 20:2245-2261.
12. Barnett S.W., Lu S., Srivastava I., Cherpelis S., Gettie A., Blanchard J., et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001, 75:5526-5540.
13. Srivastava I.K., VanDorsten K., Vojtech L., Barnett S.W., Stamatatos L. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 2003, 77:2310-2320.
14. Barillari G., Ensoli B. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin Microbiol Rev 2002, 15:310-326.
15. Fanales-Belasio E., Moretti S., Nappi F., Barillari G., Micheletti F., Cafaro A., et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 2002, 168:197-206.
16. Fanales-Belasio E., Moretti S., Fiorelli V., Tripiciano A., Pavone Cossut M.R., Scoglio A., et al. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol 2009, 182:2888-2897.
17. Caputo A., Brocca-Cofano E., Castaldello A., Voltan R., Gavioli R., Srivastava I.K., et al. Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. Vaccine 2008, 26:1214-1227.
18. Gavioli R., Cellini S., Castaldello A., Voltan R., Gallerani E., Gagliardoni F., et al. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS. Vaccine 2008, 26:727-737.
19. Gavioli R., Gallerani E., Fortini C., Fabris M., Bottoni A., Canella A., et al. HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 2004, 173:3838-3843.
20. Remoli A.L., Marsili G., Perrotti E., Gallerani E., Ilari R., Nappi F., et al. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem J 2006, 396:371-380.
21. Buttò S., Fiorelli V., Tripiciano A., Ruiz-Alvarez M.J., Scoglio A., Ensoli F., et al. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis 2003, 188:1171-1180.
22. Van Baalen C.A., Schutten M., Huisman R.C., Boers P.H., Gruters R.A., Osterhaus A.D. Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J Virol 1998, 72:6851-6857.
23. Cao J., McNevin J., Holte S., Fink L., Corey L., McElrath M.J. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 2003, 77:6867-6878.
24. Rezza G., Fiorelli V., Dorrucci M., Ciccozzi M., Tripiciano A., Scoglio A., et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 2005, 191:1321-1324.
25. Richardson M.W., Mirchandani J., Duong J., Grimaldo S., Kocieda V., Hendel H., et al. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother 2003, 57:4-14.
26. Cafaro A., Bellino S., Titti F., Maggiorella M.T., Sernicola L., Wiseman R.W., et al. Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P. J Virol 2010, 84:8953-8958.
27. Ensoli B., Fiorelli V., Ensoli F., Lazzarin A., Visintini R., Narciso P., et al. The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine 2009, 28:371-378.
28. Ensoli B., Fiorelli V., Ensoli F., Lazzarin A., Visintini R., Narciso P., et al. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS 2008, 22:2207-2209.
29. Ensoli B., Bellino S., Tripiciano A., Longo O., Francavilla V., Marcotullio S., et al. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 2010, 5:e13540.
30. Hem S.L., Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007, 6:685-698.
31. Peppoloni S., Ruggiero P., Contorni M., Morandi M., Pizza M., Rappuoli R., et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines 2003, 2:285-293.
32. Stephenson I., Zambon M.C., Rudin A., Colegate A., Podda A., Bugarini R., et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006, 80:4962-4970.
33. Barnett S.W., Srivastava I.K., Kan E., Zhou F., Goodsell A., Cristillo A.D., et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008, 22:339-348.
34. Lewis D.J., Huo Z., Barnett S., Kromann I., Giemza R., Galiza E., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009, 4:e6999.
35. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350:896-903.
36. Srivastava I.K., Stamatatos L., Kan E., Vajdy M., Lian Y., Hilt S., et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 2003, 77:11244-11259.
37. Cafaro A., Caputo A., Fracasso C., Maggiorella M.T., Goletti D., Baroncelli S., et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999, 5:643-650.
38. Mooij P., Nieuwenhuis I.G., Knoop C.J., Doms R.W., Bogers W.M., Ten Haaft P.J., et al. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. J Virol 2004, 78:3333-3342.
39. Yewdell J.W. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 2006, 25:533-543.
40. Tobin G.J., Trujillo J.D., Bushnell R.V., Lin G., Chaudhuri A.R., Long J., et al. Deceptive imprinting and immune refocusing in vaccine design. Vaccine 2008, 26:6189-6199.
41. Buckner C., Gines L.G., Saunders C.J., Vojtech L., Srivastava I., Gettie A., et al. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 2004, 320:167-180.
42. Polacino P., Larsen K., Galmin L., Suschak J., Kraft Z., Stamatatos L., et al. Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques. J Med Primatol 2008, 37(Suppl. 2):13-23.
43. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
44. Brown B.K., Karasavvas N., Beck Z., Matyas G.R., Birx D.L., Polonis V.R., et al. Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J Virol 2007, 81:2087-2091.
45. Montefiori D.C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 2009, 485:395-405.
46. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002, 46:1896-1905.
47. Takeuchi Y., McClure M.O., Pizzato M. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol 2008, 82:12585-12588.
48. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., O'Brien W.A., Ratner L., et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000, 74:8358-8367.
49. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998, 72:2855-2864.
50. Maggiorella M.T., Baroncelli S., Michelini Z., Fanales-Belasio E., Moretti S., Sernicola L., et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 2004, 22:3258-3269.
51. Goletti D., Macchia I., Leone P., Pace M., Sernicola L., Pavone-Cossut M.R., et al. Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. Med Sci Monit 2006, 12:BR330-BR340.
52. Negri D.R., Baroncelli S., Catone S., Comini A., Michelini Z., Maggiorella M.T., et al. Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. J Gen Virol 2004, 85:1191-1201.
53. Cheng-Mayer C., Levy J.A. Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann Neurol 1988, 23(Suppl):S58-S61.
54. Cheng-Mayer C., Liu R., Landau N.R., Stamatatos L. Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J Virol 1997, 71:1657-1661.
55. Stamatatos L., Lim M., Cheng-Mayer C. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2000, 16:981-994.
56. Stamatatos L., Wiskerchen M., Cheng-Mayer C. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. AIDS Res Hum Retroviruses 1998, 14:1129-1139.
57. Lieberman J., Fabry J.A., Fong D.M., Parkerson G.R. Recognition of a small number of diverse epitopes dominates the cytotoxic T lymphocytes response to HIV type 1 in an infected individual. AIDS Res Hum Retroviruses 1997, 13:383-392.
58. Bellino S., Francavilla V., Longo O., Tripiciano A., Paniccia G., Arancio A., et al. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials 2009, 4:195-204.
59. Longo O., Tripiciano A., Fiorelli V., Bellino S., Scoglio A., Collacchi B., et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 2009, 27:3306-3312.
60. Van Baalen C.A., Pontesilli O., Huisman R.C., Geretti A.M., Klein M.R., de W.F., et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997, 78(Pt 8):1913-1918.
61. Reiss P., Lange J.M., de R.A., de W.F., Dekker J., Debouck C., et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol 1990, 30:163-168.
62. Wieland U., Kuhn J.E., Jassoy C., Rubsamen-Waigmann H., Wolber V., Braun R.W. Antibodies to recombinant HIV-1 vif, tat, and nef proteins in human sera. Med Microbiol Immunol 1990, 179:1-11.
63. Richardson M.W., Mirchandani J., Silvera P., Regulier E.G., Capini C., Bojczuk P.M., et al. Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses. DNA Cell Biol 2002, 21:637-651.
64. Tikhonov I., Ruckwardt T.J., Hatfield G.S., Pauza C.D. Tat-neutralizing antibodies in vaccinated macaques. J Virol 2003, 77:3157-3166.
65. Caputo A., Gavioli R., Ensoli B. Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res 2004, 2:357-376.
66. Loomis-Price L.D., Levi M., Burnett P.R., van Hamont J.E., Shafer R.A., Wahren B., et al. Linear epitope mapping of humoral responses induced by vaccination with recombinant HIV-1 envelope protein gp160. J Ind Microbiol Biotechnol 1997, 19:58-65.
67. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678-682.
68. Polonis V.R., Brown B.K., Rosa B.A., Zolla-Pazner S., Dimitrov D.S., Zhang M.Y., et al. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 2008, 375:315-320.
69. Polonis V.R., Schuitemaker H., Bunnik E.M., Brown B.K., Scarlatti G. Impact of host cell variation on the neutralization of HIV-1 in vitro. Curr Opin HIV AIDS 2009, 4:400-407.
70. Speck R.F., Wehrly K., Platt E.J., Atchison R.E., Charo I.F., Kabat D., et al. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 1997, 71:7136-7139.
71. Suphaphiphat P., Thitithanyanont A., Paca-Uccaralertkun S., Essex M., Lee T.H. Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization. J Virol 2003, 77:3832-3837.
72. Hartley O., Klasse P.J., Sattentau Q.J., Moore J.P. V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 2005, 21:171-189.
73. Zolla-Pazner S. Improving on nature: focusing the immune response on the V3 loop. Hum Antibodies 2005, 14:69-72.
74. Mee E.T., Berry N., Ham C., Aubertin A., Lines J., Hall J., et al. Mhc haplotype M3 is associated with early control of SHIVsbg infection in Mauritian cynomolgus macaques. Tissue Antigens 2010, 76:223-229.
75. Florese R.H., Wiseman R.W., Venzon D., Karl J.A., Demberg T., Larsen K., et al. Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection. Vaccine 2008, 26:3312-3321.
76. Mee E.T., Berry N., Ham C., Sauermann U., Maggiorella M.T., Martinon F., et al. Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques. Immunogenetics 2009, 61:327-339.